Zenas BioPharma (ZBIO), which recently debuted on the Nasdaq, has lost over 66% of its share value, falling from a high of $26.25, recorded in October, to around $8.
The company's lead drug candidate is Obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, to inhibit the activity of cells involved in various autoimmune diseases, without depleting them.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com